Citation

Holt C, Butler S, Agius M, Zaman R. Psychiatr. Danub. 2011; 23 Suppl 1: S166-170.

Copyright

(Copyright © 2011, Facultas Universitatis Studiorum Zagrabiensis - Danube Symposion of Psychiatry)

DOI

unavailable

PMID

21894128

Abstract

In recent years, there has been particular interest in the use of augmentation as a strategy for the treatment of refractory depression. The purpose of this audit was to define patient factors among people receiving augmentation therapy with either mirtazepine or atypical antipsychotics. We searched an anonymised database of patients and identified those with receiving augmentation with mirtazepine (group A), atypical antipsychotics (group B) or both (group C). The audit reveals some interesting differences in patient factors between the three groups. Knowledge about such differences is useful in practical terms because it allows doctors in the BCMHT to target therapy for different patients towards their specific needs. However, the audit cannot explain the underlying reasons for these differences.

Language: en

Keywords

Humans; Adult; Female; Male; Socioeconomic Factors; Health Status; Sex Distribution; Age Distribution; Substance-Related Disorders; Suicidal Ideation; United Kingdom; Drug Therapy, Combination; Combined Modality Therapy; Alcoholism; Mirtazapine; Depressive Disorder; Community Mental Health Services; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Family Conflict; Medical Audit; Mianserin